Abstract
In a recent issue of JAMA, Lewis et al. present long-term data on the likelihood of a link between pioglitazone and the risk of bladder cancer and ten other cancers. Their findings contradict previous concerns regarding the safety of pioglitazone, and add to the controversy surrounding interpretation of rare adverse events associated with prescription drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 655-656 |
| Number of pages | 2 |
| Journal | Nature Reviews Urology |
| Volume | 12 |
| Early online date | 29 Sept 2015 |
| DOIs | |
| Publication status | Published - 2015 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Bladder cancer
- Diabetes
- Drug safety
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver